« Back
Home /
ZFYVE19 Polyclonal Antibody

ZFYVE19 Polyclonal Antibody

Item no.	E-AB-53236-120
Manufacturer	Elabscience
Amount	120 uL
Quantity options	120 uL 20 uL 200 uL 60 uL
Category	Oncology Metabolism Diabetes Antibodies By Cell Type Hematology Leukemia Lymphoma Sarcoma Myelofibrosis Immunohistochemistry Western Blot ELISA Primary Antibodies
Type	Antibody Polyclonal
Applications	WB, IHC
Specific against	Human (Homo sapiens)
Host	Rabbit
Isotype	IgG
Conjugate/Tag	Unconjugated
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	Abscission/NoCut checkpoint regulator, ANCHR, MLL partner containing FYVE domain, MPFYVE, ZFY19, ZFYVE 19, Zfyve19, Zinc finger FYVE domain containing protein 19, Zinc finger FYVE domain-containing protein 19, Zinc finger FYVE type containing 19, Zinc finger, FYVE domain containing 19
Similar products	MPFYVE, Zinc finger FYVE domain-containing protein 19, MLL partner containing FYVE domain, ZFY19, Zfyve19, Zinc finger, Abscission/NoCut checkpoint regulator, ANCHR, ZFYVE 19, Zinc finger FYVE domain containing protein 19, Zinc finger FYVE type containing 19, FYVE domain containing 19
Shipping Condition	Cool pack
Hazard information	Comply with cargo safety certificate
Available
Manufacturer - Category	Primary Antibodies
Manufacturer - Targets	ZFYVE19
Shipping Temperature	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.
Storage Conditions	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Calculated Molecular Weight	52 kDa
Observed Molecular Weight	Refer to figures
Manufacturer - Research Areas	Cell Biology
Background	ZFYVE19 (zinc finger, FYVE domain containing 19), also known as MPFYVE (MLL partner containing FYVE domain), is a 471 amino acid protein that contains one FYVE-type zinc finger. Expressed in heart, brain, kidney, skeletal muscle and liver, ZFYVE19 may participate in transcriptional regulation events within the cell. Defects in the gene encoding ZFYVE19 are associated with acute myeloblastic leukemia (AML), a rapidly progressing cancer of the myeloid line of white blood cells that is characterized by fever, anemia, bone pain, shortness of breath and frequent infections. Three isoforms of ZFYVE19 exist due to alternative splicing events.
Concentration	2 mg/mL
Buffer	PBS with 0.05% NaN3 and 40% Glycerol, pH7.4
Purification Method	Antigen affinity purification
Recommended Dilution	WB 1:500-1:2000; IHC 1:50-1:200
Abbreviation	ZFYVE19
Clonality	Polyclonal
Immunogen	Synthetic peptide of human ZFYVE19
Category ID III	Polyclonal Antibodies

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.